Relapsed or Refractory Solid Tumors
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
EisaiLenvatinib
Mereo BioPharmaOMP-52M51
Clinical Trials (2)
Total enrollment: 127 patients across 2 trials
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Start: Jul 2020Est. completion: Feb 2025127 patients
Phase 2Completed
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Start: Feb 2013Est. completion: Jul 2016
Phase 1Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3h ago
Office Administrator
SystImmune
3h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space